炎琥宁注射剂治疗流行性腮腺炎疗效的循证评价

摘要

目的:系统评价炎琥宁注射剂治疗流行性腮腺炎的疗效,探索省增补基本药物循证评价的有效方式,为新版基本药物目录遴选提供参考.方法:计算机检索PubMed、中国期刊全文数据库(CJFD)、万方数据库、中文科技期刊数据库(VIP),收集炎琥宁注射剂单用或者联合其他阳性药物(试验组)对比其他阳性药物(对照组)治疗流行性腮腺炎的随机对照试验(RCT),采用改良的Jadad评分量表评价质量后,提取有效数据采用Rev Man 5.3统计软件进行Meta分析.结果:共纳入26项RCT,合计2613例患者.Meta分析结果显示,试验组患者总有效率[OR=5.28,95%CI(3.92,7.11),P<0.001]显著高于对照组,退热时间[MD=-1.97,95%CI(-2.83,-1.12),P<0.001]、肿胀消退时间[MD=-2.05,95%CI(-2.53,-1.58),P<0.001]、疼痛消失时间[MD=-1.39,95%CI(-2.02,-0.75),P<0.001]均显著短于对照组,差异均有统计学意义.结论:炎琥宁注射剂治疗流行性腮腺炎疗效较好,可显著缩短患者退热时间、肿胀消退时间和疼痛消失时间.%OBJECTIVE:To systematically evaluate therapeutic efficacy of Yanhuning injection in the treatment of epidemic mumps,explore valid way of evidence-based review,provide reference for the selection of new essential medicine list. METH-ODS:Retrieved from PubMed,CJFD,Wanfang database and VIP,randomized controlled trials(RCTs)about Yanhuning injection alone or combined with other positive drugs(trial group)vs. other positive drugs(control group)in the treatment of epidemic mumps. Meta-analysis was conducted by using Rev Man 5.3 statistical software after quality evaluation by modified Jadad scale. RE-SULTS:Totally 26 RCTs were included,involving 2613 patients. Results of Meta-analysis showed,overall response rate [OR=5.28,95%CI(3.92,7.11),P<0.001] of trial group was significantly higher than that of control group;defervescence time [MD=-1.97,95%CI(-2.83,-1.12),P<0.001],swelling disappearance time [MD=-2.05,95%CI(-2.53,-1.58),P<0.001] and pain disappearance time [MD=-1.39,95%CI(-2.02,-0.75),P<0.001] of trial group were significantly shorter than those of control group,there was statistical significance. CONCLUSIONS:Yanhuning injection has good curative effect for epidemic mumps,and can significantly shorten defervescence time,swelling disappearance time and pain disappearance time.